---
title: "Cagrilintide"
slug: "cagrilintide"
type: "compound"
category: "Body Composition"
url: "https://peptidesciencethailand.com/compounds/cagrilintide"
description: "A long-acting amylin analogue under investigation for appetite and weight regulation, including combination trials. Mechanism, early trial data, and outlook."
---
# Cagrilintide

*Long-Acting Amylin Analogue, Next-Generation Appetite and Metabolic Regulation*

**Category:** Body Composition  
**Format:** Lyophilized Vial  
**Amount:** 5mg  
**Purity:** >98% (HPLC)

## Overview

Cagrilintide is a long-acting acylated analogue of amylin, a 37-amino-acid peptide hormone naturally co-secreted with insulin from pancreatic beta cells in response to food intake. While amylin has been recognized since the late 1980s as a key regulator of post-meal glucose metabolism and satiety signaling, its therapeutic potential was limited by the native hormone's extremely short half-life of approximately 13 minutes. Cagrilintide overcomes this limitation through fatty acid acylation, extending its half-life to approximately one week, enabling once-weekly subcutaneous administration.

Cagrilintide exerts its effects primarily through the amylin receptor complex, which consists of the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMPs), predominantly RAMP1, RAMP2, and RAMP3. These receptor complexes are expressed in key brain regions involved in appetite regulation, including the area postrema and the nucleus of the solitary tract in the brainstem. Activation of these receptors triggers signaling cascades that reduce food intake through enhanced satiety signaling, slow gastric emptying to promote prolonged fullness, and suppress glucagon secretion to improve post-meal glucose control.

What distinguishes cagrilintide in the metabolic peptide landscape is its complementary mechanism to GLP-1 receptor agonists like semaglutide. While GLP-1 agonists primarily enhance incretin signaling and insulin secretion, cagrilintide works through the amylin pathway, which modulates appetite through distinct neural circuits. This mechanistic distinction has led to the development of CagriSema, a combination of cagrilintide and semaglutide currently in Phase III clinical trials, which has demonstrated up to 22.7% body weight reduction in the REDEFINE 1 trial, exceeding the results of either compound alone.

Phase II clinical trial data published in The Lancet demonstrated dose-dependent weight loss with cagrilintide monotherapy, achieving up to 10.8% body weight reduction over 26 weeks at the highest dose tested. The combination with semaglutide showed additive effects, supporting the hypothesis that targeting multiple appetite regulation pathways simultaneously produces superior outcomes. The safety profile in clinical trials has been generally consistent with other injectable metabolic peptides, with gastrointestinal effects (nausea, typically transient) being the most commonly reported adverse events.

## Mechanism of Action

### Step 1: Amylin Receptor Complex Binding

Cagrilintide binds to amylin receptor complexes (CTR/RAMP1-3) in the brainstem's area postrema and nucleus of the solitary tract, initiating satiety signaling cascades distinct from GLP-1 pathways.

### Step 2: Central Appetite Suppression

Amylin receptor activation modulates neuronal circuits in the brainstem and hypothalamus that regulate hunger and satiety, reducing overall food intake through enhanced meal-ending signals.

### Step 3: Gastric Emptying Modulation

Cagrilintide slows gastric emptying rate, prolonging the sensation of fullness after meals. This mechanical and hormonal effect reduces meal frequency and portion size through sustained satiety.

### Step 4: Glucagon Suppression

Activation of amylin receptors suppresses inappropriate post-meal glucagon secretion from pancreatic alpha cells, improving glucose control and reducing hepatic glucose output.

### Step 5: Sustained Action via Acylation

Fatty acid acylation enables albumin binding in the bloodstream, extending cagrilintide's half-life to approximately one week. This provides continuous receptor activation with once-weekly dosing.

## Researched Benefits

### Clinically Significant Weight Reduction

Phase II trials demonstrated up to 10.8% body weight reduction with cagrilintide monotherapy over 26 weeks. In combination with semaglutide (CagriSema), Phase III trials have shown up to 22.7% weight loss, representing one of the most effective pharmacological approaches to obesity studied to date.

### Novel Appetite Regulation Pathway

Unlike GLP-1 agonists, cagrilintide works through the amylin receptor pathway, modulating appetite through distinct brainstem circuits. This complementary mechanism offers additive benefits when combined with GLP-1 therapy and may provide benefits in individuals who have plateaued on GLP-1 monotherapy.

### Improved Glycemic Control

Through glucagon suppression and gastric emptying modulation, cagrilintide improves post-meal glucose control independent of insulin secretion. This dual metabolic benefit addresses both weight and glucose management simultaneously.

### Convenient Once-Weekly Dosing

The acylated structure extends cagrilintide's half-life to approximately one week, enabling once-weekly subcutaneous injection. This represents a significant improvement in convenience over daily-dosed metabolic peptides.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 0.25-2.4mg once weekly, subcutaneous injection with gradual dose escalation |
| Route | Subcutaneous injection |
| Duration | Ongoing under specialist supervision |
| Cycle Notes | Dose escalation protocols typically start at 0.25mg weekly and increase every 4 weeks to minimize gastrointestinal side effects. Target maintenance doses range from 1.2-2.4mg weekly based on tolerability and clinical response. |
| Reconstitution | Reconstitute with bacteriostatic water per specialist instructions. Store reconstituted solution refrigerated at 2-8°C. Inject on the same day each week at a consistent time. |

> **Specialist note:** A your specialist will determine the dose escalation schedule based on tolerability, metabolic response, and weight loss trajectory. Regular monitoring of metabolic markers, body composition, and gastrointestinal tolerance is essential.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 5mg per vial |
| Purity | >98% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Molecular Weight | ~3990 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. |
| Appearance | White to off-white lyophilized powder |

## Medical Guidance

Cagrilintide is a newer metabolic peptide with a growing but still limited clinical evidence base compared to established GLP-1 agonists. Its effects on gastric emptying and appetite regulation require careful medical assessment, particularly in individuals with gastroparesis, eating disorders, pancreatitis history, or those taking other metabolic medications. Combination with GLP-1 agonists should only be managed by experienced specialists.

## Frequently Asked Questions

### What is cagrilintide and how is it different from semaglutide?

Cagrilintide is a long-acting amylin analogue, while semaglutide is a GLP-1 receptor agonist. They work through different receptor systems and neural circuits to reduce appetite. Amylin primarily modulates satiety through brainstem receptors and slows gastric emptying, while GLP-1 enhances incretin signaling. Their complementary mechanisms are why the combination (CagriSema) shows superior weight loss results.

### What clinical evidence supports cagrilintide?

Phase II trials published in The Lancet demonstrated dose-dependent weight loss up to 10.8% over 26 weeks. The Phase III REDEFINE program studying cagrilintide combined with semaglutide has shown up to 22.7% body weight reduction. Cagrilintide is still in clinical development and not yet individually approved by major regulatory agencies.

### What are the common side effects of cagrilintide?

The most commonly reported side effects in clinical trials are gastrointestinal: nausea (typically transient and dose-related), reduced appetite, and occasional diarrhea or constipation. Gradual dose escalation over several weeks significantly reduces the incidence and severity of these effects. A specialist will design an escalation schedule to optimize tolerability.

### Can cagrilintide be combined with other peptides?

The primary combination studied in clinical trials is cagrilintide with semaglutide (CagriSema), which has demonstrated superior weight loss outcomes. Any combination protocol must be designed and monitored by a specialist who can assess drug interactions, adjust dosing, and monitor metabolic markers throughout treatment.

### What medical guidance applies to cagrilintide?

Cagrilintide is a research compound that should only be used under qualified medical supervision. Baseline metabolic assessment including fasting glucose, HbA1c, lipid panel, liver function, and body composition analysis is essential. Individuals with a history of pancreatitis, medullary thyroid carcinoma, or eating disorders require special evaluation.

## References

1. **Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial** — The Lancet — 2023
2. **CagriSema once weekly versus semaglutide once weekly in adults with overweight or obesity (REDEFINE 1): a randomised, open-label, phase 3 trial** — The Lancet — 2025
3. **Amylin and calcitonin: pharmacology and prospects for clinical application** — Pharmacology & Therapeutics — 2015

## Related Compounds

- /compounds/semaglutide
- /compounds/tirzepatide
- /compounds/retatrutide